Interpace Biosciences, Inc.
(Other OTC/NBB : IDXG)

( )
IDXG After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Services » Servicestothe Health Industry
symbolcompany%chnglast%shortavg$volume
IQVIQVIA Holdings, Inc. -2.85%259.080.0%$226.36m
DGXQuest Diagnostics, Inc. -5.07%148.754.7%$187.29m
LHLaboratory Corp. of America Holdings -2.25%285.342.4%$175.30m
AMEHApollo Medical Holdings, Inc. -3.18%93.670.0%$46.25m
NOTVInotiv, Inc. -1.16%52.000.0%$9.90m
NRCNational Research Corp. -1.48%40.050.0%$1.44m
PLXProtalix Biotherapeutics, Inc. 0.32%0.9418.5%$0.79m
QIPTQuipt Home Medical Corp. -0.96%6.220.0%$0.76m
PMDPsychemedics Corp. -3.45%7.840.7%$0.12m

Company Profile

Interpace Biosciences, Inc. operates as an bioinformatics company, which engages in the development and commercialization of molecular diagnostic test and pathology services. It offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion molecular test that can aid in pancreatic cyst diagnosis and pancreatic cancer risk assessment; ThyGenX and PathFinderTG which assesses thyroid nodules for risk of malignancy; and ThyraMIR, which assesses thyroid nodules for risk of malignancy utilizing a proprietary gene expression assay. The company was founded by John P. Dugan in 1987 and is headquartered in Parsippany, NJ.